Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | PSMB8 | P28062 | 11/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 7/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.50 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.50 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.50 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.50 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.50 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.50 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.50 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15568780 | 1.00 | CTSS (0.58) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL15594256 | 1.00 | CTSS (0.58) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL15568779 | 1.00 | CTSS (0.58) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL12052789 | 0.90 | PSMB8 (0.59) | PSMB8PSMB9PSMB5PSMB1PSMB10 | |
| SCHEMBL8107326 | 0.90 | PSMB8 (0.59) | PSMB8PSMB9PSMB5PSMB1PSMB10 | |
| SCHEMBL18084172 | 0.89 | PSMB5 (0.55) | CTSSCTSKCTSLCTSBPSMB8 | |
| SCHEMBL21983221 | 0.89 | PSMB8 (0.66) | PSMB8PSMB9PSMB5PSMB1PSMB10 | |
| SCHEMBL20821163 | 0.89 | PSMB5 (0.55) | CTSSCTSKCTSLCTSBPSMB8 | |
| SCHEMBL16119201 | 0.89 | PSMB8 (0.66) | PSMB8PSMB9PSMB5PSMB1PSMB10 | |
| SCHEMBL17706117 | 0.89 | PSMB5 (0.65) | CTSBPSMB8PSMB9PSMB5PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867202-B1 | METHOD FOR PRODUCING STEREOSELECTIVE EPOXYKETONE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-12-01 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-9187442-B2 | Method for producing stereoselective epoxyketone compound | NISSAN CHEMICAL INDUSTIES, LTD. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| CN-104797591-A | Fluorinated epoxyketone compounds and their use as proteasome inhibitors | SLASSI ABDELMALIK | 2015-07-22 | — | — | CN | disclosed |
| EP-2885314-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | Fluorinov Pharma Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| US-20150126755-A1 | METHOD FOR PRODUCING STEREOSELECTIVE EPOXYKETONE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-05-07 | — | — | US | disclosed |
| WO-2014029022-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029022-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347792-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | CTSS 1116/4885CTSK 78/4885CTSL 2486/4885 |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMA1, PSMB1, PSMB11 | CTSS 1820/4885CTSK 137/4885CTSL 1335/4885 |
| US-20150126755-A1 | METHOD FOR PRODUCING STEREOSELECTIVE EPOXYKETONE COMPOUND | HSD17B7, CYP51A1, AKR1B10 | CTSS 2773/4885CTSK 674/4885CTSL 3367/4885 |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | CTSS 1197/4885CTSK 81/4885CTSL 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.